IE 11 is not supported. For an optimal experience visit our site on another browser.

Momenta Pharmaceuticals Announces M118 Selected as a "Top 10 Cardiovascular/Metabolic Projects to Watch" Windhover Expert Panel

/ Source: GlobeNewswire

CAMBRIDGE, Mass., Oct. 26, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that its next-generation novel drug candidate, M118, was selected by an expert panel from Windhover Information and the publishers of In Vivo and Startup as one of its "Top 10 CV/Metabolic Projects to Watch".

Criteria for the "Top 10" designation included:

  • Large market, large unmet need, with increasing opportunity
  • History of the molecule and drug
  • Strong science
  • Strong company
  • Diversity of indications
  • Potential for new opportunities beyond the initial indications
  • Multi-level partnering opportunities

"We believe this recognition supports the considerable promise of our novel anticoagulant drug candidate M118 in patients with acute coronary syndromes for both medical management and in the peri-procedural setting," stated Jim Roach, M.D, SVP and Chief Medical Officer of Momenta. "M118, a low-molecular-weight heparin, was rationally designed to capture the positive attributes of both unfractionated heparin and enoxaparin in one compound. We have reported positive results from our 500 patient Phase 2a clinical trial in patients with ACS undergoing elective percutaneous coronary intervention, and look forward to finding a suitable collaborative partner to continue development of M118 in ACS." 

About M118

M118 is a novel anticoagulant that has been rationally engineered using Momenta's proprietary technology and analytical methods to provide anticoagulant therapy to patients with acute coronary syndrome (ACS). M118 is designed to interact at multiple points in the coagulation cascade by selectively binding to both anti-thrombin III and thrombin, two critical factors involved in the formation of clots. Preclinical and Phase 1 studies have shown that M118 is a potent inhibitor of multiple factors in the blood that lead to clot formation, that its anticoagulant effects can be neutralized and that its activity can be monitored with standard point-of-care assays. An anticoagulant possessing these properties has the potential to satisfy a currently unmet medical need within the ACS patient population by capturing, in a single anticoagulant therapy, the positive attributes of both UFH (reversibility, monitorability and broad inhibition of the coagulation cascade) and low molecular weight heparins (adequate bioavailability and predictable pharmacokinetics to allow for convenient subcutaneous administration).

About Momenta

Momenta Pharmaceuticals is a biotechnology company, headquartered in Cambridge, MA, specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. To receive additional information about Momenta, please visit the website at , which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

About Windhover

Windhover Information Inc., an Elsevier company, has provided analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO: The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars. For more on the company's products and services, please see .

Forward Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including our beliefs regarding the potential development and commercialization opportunity for our M118 product candidate, including the quarter ended June 30, 2010, and current and future development and commercialization efforts, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "hope," "target," "project," "goals," "potential," "predict," "might," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Momenta is providing the information in this press release as of this date and assumes no obligation to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Momenta Pharmaceuticals Beverly Holley, Director of Investor Relations (617) 395-5189